Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14551 - 14575 of 15222 in total
Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations).
Investigational
Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Investigational
Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Investigational
Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
Investigational
Bosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).
Investigational
Matched Description: … 045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and
Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).
Investigational
Investigational
Ovemotide is under investigation in clinical trial NCT00357461 (Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma).
Investigational
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and...
Investigational
Matched Description: … factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Description: … mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and
Investigational
Investigational
Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Investigational
AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Investigational
Matched Description: … It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Investigational
Matched Description: … Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and
MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and Excessive Daytime Sleepiness, among others.
Investigational
Matched Description: … treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and
Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.
Investigational
Matched Description: … studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and
Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).
Investigational
Matched Description: … under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and
MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Investigational
Matched Description: … MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics …
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
Investigational
Matched Description: … under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and
Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy …
Displaying drugs 14551 - 14575 of 15222 in total